Document is current
Any future updates will be listed below
-
Authors
Fonseca, Rodrigo https://orcid.org/0000-0001-7130-0340
Zhu, Yuan Xiao
Bruins, Laura A.
Ahmann, Joseph
de Bonolo Campos, Cecilia https://orcid.org/0000-0003-0383-9533
Braggio, Esteban https://orcid.org/0000-0003-3860-4830
Chen, Xianfeng
Arribas, Mariano https://orcid.org/0000-0003-1859-7098
Darvish, Susie
Welsh, Seth
Meermeier, Erin
Mangalaparthi, Kiran K.
Kandasamy, Richard K.
Ahmann, Greg
Wiedmeier-Nutor, J. Erin
Pandey, Akhilesh https://orcid.org/0000-0001-9943-6127
Chesi, Marta https://orcid.org/0000-0002-4024-8225
Bergsagel, P. Leif https://orcid.org/0000-0003-1523-7388
Fonseca, Rafael https://orcid.org/0000-0002-5938-3769
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA271410)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA15083)
Paula and Rodger Riney, Family Foundation
- License Information
-
More Information
Article History
Received: 23 August 2024
Revised: 21 December 2024
Accepted: 21 January 2025
First Online: 5 February 2025
Competing interests
: PLB has served as a consultant for Pfizer, Novartis, GSK, Janssen, and Oncopeptides. RF has served as a consultant for AbbVie, Amgen, Bayer, BMS/Celgene, GSK, H3 Therapeutics, Janssen, Juno, Karyopharm, Kite, Merck, Novartis, Oncopeptides, Oncotracker, Pfizer, Pharmacyclics, Regeneron, Sanofi, Takeda; and has served as an advisory board member for Adaptive Biotechnologies, Caris Life Sciences and OncoMyx. No disclosures were reported by the other authors.
